Universal or targeted screening for fetal alcohol exposure: A cost-effectiveness analysis

Therapeutic Drug Monitoring

Volumn 31, Issue 2, 2009, Pages 170-172

  Zelner, Irene ^a,b   Koren, Gideon ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cost effectiveness; Fatty acid ethyl esters; Fetal alcohol spectrum disorder; Meconium; Screening

Indexed keywords

FATTY ACID ESTER; ALCOHOL;

ALCOHOL CONSUMPTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; FETAL ALCOHOL SYNDROME; HUMAN; MECONIUM; PRENATAL EXPOSURE; PRENATAL SCREENING; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MASS SCREENING; NEWBORN; NEWBORN SCREENING; PREGNANCY; RISK FACTOR;

COST-BENEFIT ANALYSIS; ETHANOL; FEMALE; FETAL ALCOHOL SYNDROME; HUMANS; INFANT, NEWBORN; MASS SCREENING; NEONATAL SCREENING; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS;

EID: 65349172934     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31819a7b5f     Document Type: Article

References (22)

1. Hopkins RB, Paradis J, Roshankar T, et al. Universal or targeted screening for fetal alcohol exposure: A cost-effectiveness analysis. J Stud Alcohol Drugs. 2008;69:510-519.
2. US Institute of Medicine. Fetal alcohol syndrome: diagnosis, epidemiology, prevention and treatment. In: Stratton K, Howe C, Battaglia F, eds. Fetal Alcohol Syndrome. Washington, DC: National Academy Press; 1996:156-166.
3. Williams RJ, Odaibo FS, McGee JM. Incidence of fetal alcohol syndrome in northeastern Manitoba. Can J Public Health. 1999;90:192-194.
4. Sampson PD, Streissguth AP, Bookstein FL, et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology. 1997;56:317-326.
5. Burd L. Fetal alcohol syndrome. Introduction. Addict Biol. 2004;9:115-118.
6. Lupton C, Burd L, Harwood R. Cost of fetal alcohol spectrum disorders. Am J Med Genet C Semin Med Genet. 2004;127C:42-50.
7. Coles CD, Kable JA, Drews-Botsch C, et al. Early identification of risk for effects of prenatal alcohol exposure. J Stud Alcohol. 2000;61:607-616.
8. Kalberg WO, Buckley D. FASD: what types of intervention and rehabilitation are useful? Neurosci Biobehav Rev. 2007;31:278-285.
9. O'Connor MJ, Frankel F, Paley B, et al. A controlled social skills training for children with fetal alcohol spectrum disorders. J Consult Clin Psychol. 2006;74:639-648.
10. Adnams CM, Sorour P, Kalberg WO, et al. Language and literacy outcomes from a pilot intervention study for children with fetal alcohol spectrum disorders in South Africa. Alcohol. 2007;41:403-414.
11. Streissguth AP, O'Malley K. Neuropsychiatric implications and long-term consequences of fetal alcohol spectrum disorders. Semin Clin Neuropsychiatry. 2000;5:177-190.
12. Streissguth AP, Barr H, Kogan J, et al. Understanding the Occurrence of Secondary Disabilities in Clients with Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Effects (FAE). University of Washington School of Medicine: Fetal Alcohol and Drug Unit, Department of Psychiatry and Behavioral Sciences; August 1, 1996.
13. Abel EL. An update on incidence of FAS: FAS is not an equal opportunity birth defect. Neurotoxicol Teratol. 1995;17:437-443.
14. Chan D, Klein J, Karaskov T, et al. Fetal exposure to alcohol as evidenced by fatty acid ethyl esters in meconium in the absence of maternal drinking history in pregnancy. Ther Drug Monit. 2004;26:474-481.
15. Ostrea EM Jr, Hernandez JD, Bielawski DM, et al. Fatty acid ethyl esters in meconium: Are they biomarkers of fetal alcohol exposure and effect? Alcohol Clin Exp Res. 2006;30:1152-1159.
16. Canadian Pediatric Society Statement. (CPS). Fetal Alcohol Syndrome. Pediatric Child Health 2002;7:161-174.
17. Chudley AE, Conry J, Cook JL, et al. Fetal alcohol spectrum disorder: Canadian guidelines for diagnosis. Can Med Assoc J. 2005;172:S1-S21.
18. Stade B, Ungar WJ, Stevens B, et al. The burden of prenatal exposure to alcohol: measurement of cost. J FAS Int. 2006. p.e5. Available at: http://www.motherisk.org/JFAS-documents/JFAS-6005-e5.pdf. Accessed August 15, 2008.
19. Grant TM, Ernst CC, Streissguth AP. An intervention with high-risk mothers who abuse alcohol and drugs: The seattle advocacy model. Am J Public Health. 1996;86:1816-1817.
20. Klein J, Chan D, Karaskov T, et al. Prevalence of prenatal alcohol and illicit substance exposure in neonates - assessment by meconium analysis [abstract]. Ther Drug Monit. 2003;25:490.
21. Goh, YI, Hutson, JR, Roukema, H, et al. Risk of fetal alcohol exposure among newborns in a high risk unit. Clin Pharmacol Ther. 2008;83:S75.
22. Marcellus L. Is meconium screening appropriate for universal use? Science and ethics say no. Adv Neonatal Care. 2007;7:207-214.